Clinical trials

  • RILVEGOSTOMIG for Endometrial cancer | HER2-expressing endometrial cancer | Advanced or recurrent endometrial cancer
  • NEX-22A for Type 2 diabetes
  • SACITUZUMAB TIRUMOTECAN for Epithelial ovarian cancer | Primary peritoneal cancer | Fallopian tube cancer
  • SACITUZUMAB TIRUMOTECAN for Non-small cell lung cancer (resectable clinical Stage II–IIIB with N2 nodal involvement)
  • LEVOSIMENDAN for Cardiogenic shock
  • MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE for Primary myelofibrosis | Post-polycythaemia vera myelofibrosis | Post-essential thrombocythemia myelofibrosis
  • PATRITUMAB DERUXTECAN for Non-small cell lung cancer (EGFR-mutated)
  • SACITUZUMAB TIRUMOTECAN for Recurrent ovarian cancer | Platinum-sensitive recurrent ovarian cancer
  • [AL[18F]F]FAPI-74 for Cholangiocarcinoma
  • Etentamig (ABBV-383) for Relapsed or refractory multiple myeloma
  • LISAFTOCLAX for Chronic lymphocytic leukemia | Small lymphocytic lymphoma
  • Glofitamab for Relapsed or refractory B-cell non-Hodgkin lymphoma